Tuesday, Sep 8, 2026

"granules-india-limited"

Granules India Limited receives final approval from USFDA for its new drug

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged six years and older, as well as for Moderate to Severe Binge Eating Disorder (BED) in adults

Latest News

Polytechnic students demand immediate withdrawal of GO 97

21 minutes ago
Thousands of ASHA workers join ‘Chalo Assembly’ protest

41 minutes ago
Telangana: Three booked for weapon stunts during birthday celebrations

16 minutes ago
Fire safety compliance stressed at Telangana schools, colleges

1 hour ago
Hyderabad set to host seventh International Real Estate Conference

2 hours ago
‘Anaganaga’ opens in Jubilee Hills with focus on Telugu cuisine

2 hours ago
Over 58,000 forms of Ganesha: Man from Hyderabad builds world record Ganesh sanctuary

2 hours ago
BRS cadre take to streets across Khammam, target congress government

2 hours ago